Molecular determinants of plaque size as an indicator of dengue virus attenuation

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Goh, Kenneth Choon Meng ^a   Tang, Choon Kit ^a   Norton, Diana Catherine ^b   Gan, Esther Shuyi ^a   Tan, Hwee Cheng ^a   Sun, Bo ^b   Syenina, Ayesa ^a   Yousuf, Amjad ^c   Ong, Xin Mei ^a   Kamaraj, Uma Sangumathi ^a   Cheung, Yin Bun ^a   Gubler, Duane J ^a   Davidson, Andrew ^c   St John, Ashley Lauren ^a   Sessions, October Michael ^a   Ooi, Eng Eong ^a  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE;

ANIMAL; CELL LINE; DENGUE VIRUS; GENETICS; GROWTH, DEVELOPMENT AND AGING; HAMSTER; HOST PATHOGEN INTERACTION; HUMAN; IMMUNOLOGY; PHYSIOLOGY; VIRAL PLAQUE ASSAY; VIRULENCE;

ANIMALS; CELL LINE; CRICETINAE; DENGUE VACCINES; DENGUE VIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; VACCINES, ATTENUATED; VIRAL PLAQUE ASSAY; VIRULENCE;

EID: 84969194566     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26100     Document Type: Article

References (41)

1. Halstead, S. B. & Marchette, N. J. Biologic properties of dengue viruses following serial passage in primary dog kidney cells: studies at the University of Hawaii. Am J Trop Med Hyg 69, 5-11 (2003).
2. Dubes, G. R. Differences among strains of poliomyelitis viruses in plaque size on monkey kidney cells. Virology 2, 284-288 (1956).
3. Kanda, Y. & Melnick, J. L. In vitro differentiation of virulent and attenuated polioviruses by their growth characteristics on MS cells. J Exp Med 109, 9-24 (1959).
4. Bhamarapravati, N. & Sutee, Y. Live attenuated tetravalent dengue vaccine. Vaccine 18, Supplement 2, 44-47, doi: http://dx.doi.org/10.1016/S0264-410X(00)00040-2 (2000).
5. Butrapet, S. et al. Attenuation Markers of a Candidate Dengue Type 2 Vaccine Virus, Strain 16681 (PDK-53), Are Defined by Mutations in the 5,Ä≤ Noncoding Region and Nonstructural Proteins 1 and 3. J Virol 74, 3011-3019, doi: 10.1128/jvi.74.7.3011-3019.2000 (2000).
6. Enders, J. F., Katz, S. L., Milovanovic, M. V. & Holloway, A. Studies on an attenuated measles-virus vaccine. I. Development and preparations of the vaccine: technics for assay of effects of vaccination. N Engl J Med 263, 153-159, doi: 10.1056/NEJM196007282630401 (1960).
7. Buynak, E. B. & Hilleman, M. R. Live attenuated mumps virus vaccine. 1. Vaccine development. Proc Soc Exp Biol Med 123, 768-775 (1966).
8. Theiler, M. & Smith, H. H. The Use of Yellow Fever Virus Modified by in Vitro Cultivation for Human Immunization. J Exp Med 65, 787-800 (1937).
9. Smith, H. H., Penna, H. A. & Paoliello, A. Yellow Fever Vaccination with Cultured Virus (17D) without Immune Serum. Am J Trop Med Hyg s1-18, 437-468 (1938).
10. Kanesa-thasan, N. et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19, 3179-3188, doi: http://dx.doi.org/10.1016/S0264-410X(01)00020-2 (2001).
11. Plotkin, S. A., Furukawa, T., Zygraich, N. & Huygelen, C. Candidate cytomegalovirus strain for human vaccination. Infect Immun 12, 521-527 (1975).
12. Manokaran, G. et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science doi: 10.1126/science.aab3369 (2015).
13. Balas, C. et al. Different Innate Signatures Induced in Human Monocyte-derived Dendritic Cells by Wild-Type Dengue 3 Virus, Attenuated but Reactogenic Dengue 3 Vaccine Virus, or Attenuated Nonreactogenic Dengue 1,Äì4 Vaccine Virus Strains. J Infect Dis 203, 103-108, doi: 10.1093/infdis/jiq022 (2011).
14. Sanchez, V. et al. Innate and adaptive cellular immunity in flavivirus-naive human recipients of a live-attenuated dengue serotype 3 vaccine produced in Vero cells (VDV3). Vaccine 24, 4914-4926, doi: 10.1016/j.vaccine.2006.03.066 (2006).
15. Huang, C. Y.-H. et al. Dengue 2 PDK-53 Virus as a Chimeric Carrier for Tetravalent Dengue Vaccine Development. J Virol 77, 11436-11447, doi: 10.1128/jvi.77.21.11436-11447.2003 (2003).
16. Osorio, J. E., Huang, C. Y. H., Kinney, R. M. & Stinchcomb, D. T. Development of DENVax: A chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever. Vaccine 29, 7251-7260, doi: 10.1016/j.vaccine.2011.07.020 (2011).
17. Sessions, O. M. et al. Host Cell Transcriptome Profile during Wild-Type and Attenuated Dengue Virus Infection. PLos Negl Trop Dis 7, e2107, doi: 10.1371/journal.pntd.0002107 (2013).
18. Boonnak, K., Slike, B. M., Donofrio, G. C. & Marovich, M. A. Human Fcγ RII Cytoplasmic Domains Differentially Influence Antibody-Mediated Dengue Virus Infection. J Immunol 190, 5659-5665, doi: 10.4049/jimmunol.1203052 (2013).
19. Wu, S. J. et al. Human skin Langerhans cells are targets of dengue virus infection. Nat Med 6, 816-820, doi: 10.1038/77553 (2000).
20. Tassaneetrithep, B. et al. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197, 823-829, doi: 10.1084/jem.20021840 (2003).
21. Chan, K. R. et al. Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci USA 108, 12479-12484, doi: 10.1073/pnas.1106568108 (2011).
22. Chan, K. R. et al. Leukocyte immunoglobulin-like receptor B1 is critical for antibody-dependent dengue. Proc Natl Acad Sci USA 111, 2722-2727, doi: 10.1073/pnas.1317454111 (2014).
23. Schoggins, J. W. et al. Dengue reporter viruses reveal viral dynamics in interferon receptor-deficient mice and sensitivity to interferon effectors in vitro. Proc Natl Acad Sci USA 109, 14610-14615, doi: 10.1073/pnas.1212379109 (2012).
24. St John, A. L., Rathore, A. P., Raghavan, B., Ng, M.-L. & Abraham, S. N. Contributions of mast cells and vasoactive products, leukotrienes and chymase, to dengue virus-induced vascular leakage. eLife 2, doi: 10.7554/eLife.00481 (2013).
25. St John, A. L. et al. Immune surveillance by mast cells during dengue infection promotes natural killer (NK) and NKT-cell recruitment and viral clearance. Proc Natl Acad Sci USA 108, 9190-9195, doi: 10.1073/pnas.1105079108 (2011).
26. Sabin, A. B. et al. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 173, 1521-1526 (1960).
27. Querec, T. D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10, 116-125, doi: http://www.nature.com/ni/journal/v10/n1/suppinfo/ni.1688-S1.html (2009).
28. Pulendran, B. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat Rev Immunol 9, 741-747 (2009).
29. Sui, Y. et al. Innate and adaptive immune correlates of vaccine and adjuvant-induced control of mucosal transmission of SIV in macaques. Proc Natl Acad Sci USA 107, 9843-9848, doi: 10.1073/pnas.0911932107 (2010).
30. Levitz, S. M. & Golenbock, D. T. Beyond Empiricism: Informing Vaccine Development through Innate Immunity Research. Cell 148, 1284-1292, doi: 10.1016/j.cell.2012.02.012 (2012).
31. Rabablert, J. et al. Attenuating characteristics of DEN-2 PDK53 in flavivirus-naive peripheral blood mononuclear cells. Vaccine 25, 3896-3905, doi: 10.1016/j.vaccine.2007.01.096 (2007).
32. Frierson, J. G. The yellow fever vaccine: a history. Yale J Biol Med 83, 77-85 (2010).
33. Plotkin, S. A. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis 43 Suppl 3, S164-168, doi: 10.1086/505950 (2006).
34. Elek, S. D. & Stern, H. Development of a vaccine against mental retardation caused by Cytomegalovirus infection in utero. Lancet 303, 1-5, doi: 10.1016/S0140-6736(74)92997-3.
35. Kinney, R. M. et al. Construction of Infectious cDNA Clones for Dengue 2 Virus: Strain 16681 and Its Attenuated Vaccine Derivative, Strain PDK-53. Virology 230, 300-308, doi: 10.1006/viro.1997.8500 (1997).
36. Martin, N. C. et al. An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of antidengue neutralizing antibodies. J Virol Methods 134, 74-85, doi: 10.1016/j.jviromet.2005.12.002 (2006).
37. Lidbury, B. A. & Mahalingam, S. Dengue virus and host antibody: a dangerous balancing act. Lancet Infect Dis 14, 783-784, doi: http://dx.doi.org/10.1016/S1473-3099(14)70843-6 (2014).
38. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550, doi: 10.1073/pnas.0506580102 (2005).
39. Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34, 267-273, doi: 10.1038/ng1180 (2003).
40. Lai, Y.-L. et al. Cost-Effective Real-Time Reverse Transcriptase PCR (RT-PCR) To Screen for Dengue Virus followed by Rapid Single-Tube Multiplex RT-PCR for Serotyping of the Virus. J Clin Microbiol 45, 935-941, doi: 10.1128/JCM.01258-06 (2007).
41. Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675 (2012).